Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Molecular Partners
Develops a proprietary new class of drugs called DARPins - "Antibody v. 2.0"
Transaction Summary
Completed a $100M IPO in 2014
Lead product, abicipar, started pivotal Phase III clinical trials for AMD - leading cause of blindness
Zurich-Schlieren, Switzerland
SIX: MOLN
Contact:
Petri Vainio
IPO
Related News
Molecular Partners Received a European Small and Mid-Cap Award
Molecular Partners Secures CHF 46 million in Series B Financing Led by Essex Woodlands
Molecular Partners Wins European Biotechnica Award 2015
Bill Burns Nominated for Election to Molecular Partners’ Board of Directors